Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc., an RNA oncology company, has regained compliance with the Nasdaq's stockholders' equity requirement for continued listing on the Nasdaq Capital Market, as notified by the Nasdaq Office of General Counsel on January 26, 2024. The company, which is listed under the trading symbol RNAZ, had previously been out of compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000. Following the compliance, TransCode will be monitored by a mandatory panel through January 26, 2025. Additionally, TransCode received a separate notification from Nasdaq on November 7, 2023, regarding non-compliance with the minimum bid price rule. The company must maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days before May 6, 2024, to regain compliance. TransCode is a clinical-stage company focused on developing RNA therapeutics for treating metastatic cancer, with its lead candidate, TTX-MC138, targeting metastatic tumors.
TransCode Therapeutics, Inc., an RNA oncology company, has regained compliance with the Nasdaq's stockholders' equity requirement for continued listing on the Nasdaq Capital Market, as notified by the Nasdaq Office of General Counsel on January 26, 2024. The company, which is listed under the trading symbol RNAZ, had previously been out of compliance with the Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000. Following the compliance, TransCode will be monitored by a mandatory panel through January 26, 2025. Additionally, TransCode received a separate notification from Nasdaq on November 7, 2023, regarding non-compliance with the minimum bid price rule. The company must maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days before May 6, 2024, to regain compliance. TransCode is a clinical-stage company focused on developing RNA therapeutics for treating metastatic cancer, with its lead candidate, TTX-MC138, targeting metastatic tumors.
根据纳斯达克总法律顾问办公室于2024年1月26日发布的通知，RNA肿瘤学公司TransCode Therapeutics, Inc. 已恢复遵守纳斯达克继续在纳斯达克资本市场上市的股东权益要求。该公司以交易代码RNAZ上市，此前曾不遵守纳斯达克上市规则5550（b）（1），该规则要求最低股东权益为250万美元。合规后，TransCode将由一个强制性小组进行监督，直至2025年1月26日。此外，TransCode于2023年11月7日收到了来自纳斯达克的另一份通知，内容涉及未遵守最低出价规则。该公司必须在2024年5月6日之前至少连续10个交易日将最低收盘价维持在1.00美元或以上，以恢复合规。TransCode是一家处于临床阶段的公司，专注于开发用于治疗转移性癌症的RNA疗法，其主要候选药物 TTX-MC138 是针对转移性肿瘤的。
根据纳斯达克总法律顾问办公室于2024年1月26日发布的通知，RNA肿瘤学公司TransCode Therapeutics, Inc. 已恢复遵守纳斯达克继续在纳斯达克资本市场上市的股东权益要求。该公司以交易代码RNAZ上市，此前曾不遵守纳斯达克上市规则5550（b）（1），该规则要求最低股东权益为250万美元。合规后，TransCode将由一个强制性小组进行监督，直至2025年1月26日。此外，TransCode于2023年11月7日收到了来自纳斯达克的另一份通知，内容涉及未遵守最低出价规则。该公司必须在2024年5月6日之前至少连续10个交易日将最低收盘价维持在1.00美元或以上，以恢复合规。TransCode是一家处于临床阶段的公司，专注于开发用于治疗转移性癌症的RNA疗法，其主要候选药物 TTX-MC138 是针对转移性肿瘤的。
有用
没用